JP2005518354A - コドラッグを含有する医薬組成物 - Google Patents

コドラッグを含有する医薬組成物 Download PDF

Info

Publication number
JP2005518354A
JP2005518354A JP2003545335A JP2003545335A JP2005518354A JP 2005518354 A JP2005518354 A JP 2005518354A JP 2003545335 A JP2003545335 A JP 2003545335A JP 2003545335 A JP2003545335 A JP 2003545335A JP 2005518354 A JP2005518354 A JP 2005518354A
Authority
JP
Japan
Prior art keywords
component
agents
pharmaceutical composition
codrug
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
JP2003545335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005518354A5 (https=
Inventor
エイ．ウォルターズ ケニス
シミズ ロバート
アシュトン ポール
シンコウスカ グラツィナ
シンコウスキ ターデウーシュ
ゴティエ エリック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eyepoint Pharmaceuticals US Inc
Original Assignee
Psivida US Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida US Inc filed Critical Psivida US Inc
Publication of JP2005518354A publication Critical patent/JP2005518354A/ja
Publication of JP2005518354A5 publication Critical patent/JP2005518354A5/ja
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2003545335A 2001-11-19 2002-11-19 コドラッグを含有する医薬組成物 Abandoned JP2005518354A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33151201P 2001-11-19 2001-11-19
PCT/US2002/037035 WO2003043657A1 (en) 2001-11-19 2002-11-19 Topical delivery of codrugs

Publications (2)

Publication Number Publication Date
JP2005518354A true JP2005518354A (ja) 2005-06-23
JP2005518354A5 JP2005518354A5 (https=) 2006-01-19

Family

ID=23294274

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003545335A Abandoned JP2005518354A (ja) 2001-11-19 2002-11-19 コドラッグを含有する医薬組成物

Country Status (6)

Country Link
US (3) US20030118528A1 (https=)
EP (1) EP1448231A1 (https=)
JP (1) JP2005518354A (https=)
AU (1) AU2002350207A1 (https=)
CA (1) CA2467559A1 (https=)
WO (1) WO2003043657A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014507391A (ja) * 2010-12-17 2014-03-27 ネオンク テクノロジーズ インク． イソペリリルアルコールの使用方法および装置
JP2016520638A (ja) * 2013-06-04 2016-07-14 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システム
JP2021512852A (ja) * 2018-02-02 2021-05-20 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用
US12383621B2 (en) 2010-08-27 2025-08-12 University Of Southern California Pharmaceutical compositions comprising POH derivatives

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6417227B1 (en) * 1999-04-28 2002-07-09 Cg And Associates Methods of delivery of cetyl myristoleate
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
NZ528994A (en) * 2001-04-26 2006-02-24 Control Delivery Sys Inc Sustained release drug delivery system containing codrugs
JP4814486B2 (ja) * 2001-06-05 2011-11-16 シヴィダ・インコーポレイテッド 持続放出性鎮痛性化合物
IN2014DN10834A (https=) * 2001-09-17 2015-09-04 Psivida Inc
AU2002350207A1 (en) * 2001-11-19 2003-06-10 Control Delivery Systems, Inc. Topical delivery of codrugs
EP1461122A4 (en) * 2001-12-10 2006-08-23 Control Delivery Sys Inc TREATMENT OF DISEASES OF THE UROGENITAL SYSTEM
US20040022815A1 (en) * 2002-08-05 2004-02-05 Orchid Health Care Novel pharmaceutical composition of ceftiofur
WO2005009480A2 (en) * 2003-06-11 2005-02-03 Control Delivery Systems, Inc. Implants containing codrugs
US8267914B1 (en) * 2003-10-16 2012-09-18 University Of Notre Dame Du Lac Method and apparatus for AC electrospray
US9248146B2 (en) * 2003-10-24 2016-02-02 Adhesives Research, Inc. Dissolvable adhesive films for delivery of pharmaceutical or cosmetic agents
WO2005039499A2 (en) 2003-10-24 2005-05-06 Adhesives Research, Inc. Rapidly disintegrating film
EP1744787A4 (en) * 2004-05-14 2011-04-06 Interface Biologics Inc POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US20060222692A1 (en) * 2005-03-31 2006-10-05 Fairfield Clinical Trials Llc Method and compositions for transdermal administration of antimicrobial medications
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
WO2008115590A1 (en) * 2007-03-21 2008-09-25 Alza Corporation Apparatus and method for transdermal delivery of a benzodiazepine
WO2008146224A2 (en) 2007-05-25 2008-12-04 Compex Medical S.A. Wound healing electrode set
WO2009143299A1 (en) 2008-05-20 2009-11-26 Neurogesx, Inc. Hepatoprotectant acetaminophen mutual prodrugs
WO2010022326A2 (en) * 2008-08-22 2010-02-25 Us Worldmeds Llc Transdermal delivery of apomorphine using microneedles
US20100086581A1 (en) * 2008-10-07 2010-04-08 Ernest Bove Method for purpura reduction and prevention
US11731991B2 (en) 2008-11-03 2023-08-22 Lehigh University Augmenting moieties for anti-inflammatory compounds
DE102009008256A1 (de) * 2009-02-10 2010-08-12 Lts Lohmann Therapie-Systeme Ag Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut
BRPI0900238A2 (pt) 2009-02-12 2010-10-26 Arch Chem Inc composição antimicrobiana e processo para controle da contaminação microbiana em processos de fermentação alcóolica
KR101751906B1 (ko) 2009-03-04 2017-06-29 엠플리큐어 아베 새로운 오용 방지 배합물
EP2427177B1 (en) 2009-05-08 2018-03-28 Emplicure AB Composition for sustained drug delivery comprising geopolymeric binder
JP5833007B2 (ja) 2009-08-31 2015-12-16 ドクター・レディーズ・ラボラトリーズ・リミテッド ステロイドを含む局所製剤
NO2613784T3 (https=) * 2010-09-07 2018-05-12
EP2630952A1 (en) * 2012-02-23 2013-08-28 Novagali Pharma S.A. Self-preserved oil dispersions comprising boric acid
BR112015021388A2 (pt) 2013-03-08 2017-07-18 Allergan Inc conjugados esteroides de ciclosporina a
RU2015138891A (ru) 2013-03-08 2017-04-11 Аллерган, Инк. Конъюгаты антибиотиков, напрямую связанные со стероидными препаратами
US9512068B2 (en) 2013-03-15 2016-12-06 Rutgers, The State University Of New Jersey Augmenting moieties for anti-inflammatory compounds
US20160184431A1 (en) 2014-03-11 2016-06-30 Promius Pharma Llc Topical compositions comprising a corticosteroid
IL255290B2 (en) 2015-04-27 2024-01-01 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Substances that bind to EGF1 and their use in the treatment of inflammatory diseases and tumors
BR112018000217A2 (pt) 2015-07-15 2018-09-04 Celator Pharmaceuticals Inc sistemas de distribuição de nanopartículas aperfeiçoados
US10286095B2 (en) 2015-09-11 2019-05-14 Olson Ip Technologies, Inc. Travel kit
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물
WO2017165502A1 (en) * 2016-03-22 2017-09-28 The General Hospital Corporation Compositions and methods for topical delivery of pharmaceutical agents
WO2018081389A1 (en) * 2016-10-26 2018-05-03 Georgia State University Research Foundation, Inc. Devices and methods for the treatment of a zoonotic herpesvirus infection
EP3600324A4 (en) 2017-03-23 2020-12-09 Graybug Vision, Inc. COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF EYE DISORDERS
AU2018265415A1 (en) 2017-05-10 2019-10-31 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
EP3996764A4 (en) * 2019-07-10 2023-11-01 Ripple Therapeutics Corporation SURFACE COATINGS, IMPLANTABLE DEVICES COMPRISING DIMER STEROID PRODRUGS AND USES THEREOF
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
US11389409B2 (en) * 2019-08-30 2022-07-19 Remedy Diagnostics LLC Transdermal device comprising acetaminophen prodrug
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
CN113332588B (zh) * 2021-05-26 2023-05-09 四川大学 用于口腔黏膜给药的尖端载药可溶性微针贴片及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) * 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US3147183A (en) * 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
FR2576213B1 (fr) * 1985-01-21 1989-02-24 Cortial Nouveau procede d'obtention de formes pharmaceutiques a liberation prolongee
US5028431A (en) * 1987-10-29 1991-07-02 Hercon Laboratories Corporation Article for the delivery to animal tissue of a pharmacologically active agent
TW225536B (https=) * 1990-08-23 1994-06-21 Ciba Geigy Ag
US5681964A (en) * 1990-10-23 1997-10-28 University Of Kentucky Research Foundation Permeable, non-irritating prodrugs of nonsteroidal and steroidal agents
CA2132342A1 (en) * 1992-04-06 1993-10-14 Kenneth F. Buechler Novel opiate derivatives and protein and polypeptide opiate derivative conjugates and labels
US5552162A (en) * 1993-02-09 1996-09-03 Arch Development Corporation Method for improvement of scar size and appearance
US6051576A (en) * 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
US5840731A (en) * 1995-08-02 1998-11-24 Virginia Commonwealth University Pain-alleviating drug composition and method for alleviating pain
DE19607395C2 (de) * 1996-02-28 2002-11-21 Lohmann Therapie Syst Lts Salze aus einem kationischen narkotischen Analgetikum mit einem anionischen nichtnarkotischen Analgetikum, Verfahren zu deren Herstellung und die diese Salze enthaltenden pharmazeutischen Präparate
US6593292B1 (en) * 1999-08-24 2003-07-15 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
FR2803849B1 (fr) * 2000-01-19 2002-04-19 Centre Nat Rech Scient Molecules chimeres formees de psoralene et de retinoide, leur procede de preparation, et leurs applications au traitement de pathologies de l'hyperproliferation cellulaire et notamment du psoriasis
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
AU2002350207A1 (en) * 2001-11-19 2003-06-10 Control Delivery Systems, Inc. Topical delivery of codrugs
WO2003061626A1 (en) * 2002-01-18 2003-07-31 Control Delivery Systems, Inc. Polymeric gel system for the controlled delivery of codrugs

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12383621B2 (en) 2010-08-27 2025-08-12 University Of Southern California Pharmaceutical compositions comprising POH derivatives
JP2014507391A (ja) * 2010-12-17 2014-03-27 ネオンク テクノロジーズ インク． イソペリリルアルコールの使用方法および装置
JP2017125024A (ja) * 2010-12-17 2017-07-20 ネオンク テクノロジーズ インク． イソペリリルアルコールの使用方法および装置
US9987237B2 (en) 2010-12-17 2018-06-05 Neonc Technologies, Inc. Methods and devices for using isoperillyl alcohol
JP2016520638A (ja) * 2013-06-04 2016-07-14 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システム
US11529345B2 (en) 2013-06-04 2022-12-20 Lts Lohmann Therapie-Systeme Ag Buprenorphine transdermal delivery system
JP2021512852A (ja) * 2018-02-02 2021-05-20 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用
JP7502186B2 (ja) 2018-02-02 2024-06-18 リップル セラピューティクス コーポレーション ステロイド二量体を含むガラス製剤およびその使用

Also Published As

Publication number Publication date
CA2467559A1 (en) 2003-05-30
US20080107720A1 (en) 2008-05-08
AU2002350207A1 (en) 2003-06-10
US20030118528A1 (en) 2003-06-26
WO2003043657A1 (en) 2003-05-30
US20070082041A1 (en) 2007-04-12
EP1448231A1 (en) 2004-08-25

Similar Documents

Publication Publication Date Title
JP2005518354A (ja) コドラッグを含有する医薬組成物
JP2005518354A5 (https=)
JP5105697B2 (ja) コドラッグのコントロールデリバリ用ポリマー性ゲルシステム
JP5628467B2 (ja) 生体分解性徐放性ドラッグデリバリーシステム
US20040180036A1 (en) Salts of codrugs and uses related thereto
EP2123274B1 (en) Medicinal composition for transdermal absorption, medicinal composition storing unit and transdermal absorption preparation using the same
TW413637B (en) Preparation for percutaneous absorption
ES2549924T3 (es) Análogos de ácido araquidónico y métodos para tratamiento analgésico usando el mismo
PT1962817E (pt) Administração transdérmica de uma forma de sal de meptazinol
US20230128252A1 (en) Pharmaceutical compositions
JP4746856B2 (ja) ピラゾロン系製剤
JP3187806B2 (ja) ニトロイミダゾール系化合物を含むアトピー性皮膚炎治療用の外用剤
JP2001270826A (ja) 皮膚疾患治療・予防用外用剤
JP6566707B2 (ja) 経皮唾液腺投与用の唾液分泌促進剤
JP3568881B2 (ja) 皮膚疾患治療用外用剤
ES2356563T3 (es) Administración transdérmica de meptazinol.
JP3538367B2 (ja) 皮膚組織障害治療・予防・改善用外用剤
WO2019008472A1 (en) PHARMACEUTICAL COMPOSITIONS OF LIGNOCAINE HCL
JP2001288082A (ja) 乾癬治療・予防用外用剤
HK1174895B (en) Arachidonic acid analogs and methods for analgesic treatment using same
JP2014524924A (ja) ３−［（１ｓ，２ｓ）−３−（ジメチルアミノ）−１−エチル−２−メチルプロピル］フェノールのくも膜下投与または硬膜外投与

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20051118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20051118

A762 Written abandonment of application

Free format text: JAPANESE INTERMEDIATE CODE: A762

Effective date: 20081022